Geron Corporation
NASDAQ:GERNBiotechnology
+$0.05 today
- Market cap
- $638.38M
- Beta
- 0.60
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.10
Volume 34.97M
Average 16.28M
GERN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Geron CorporationNASDAQ: GERN
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $35.43M fell 11.5% year over year, behind the -2.5% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 15.0% from the prior quarter. Over 3 fiscal years it compounded at +54.0% a year.
Context
- Selling, general & admin amounted to 86.6% of revenue in FY2025, down 102.7 pp from a year earlier.
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $18.3B (+11391.5%) for the fiscal year ending Dec 2026, a step up from the +9.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $35.43M-15.0% QoQ
- Last fiscal yearDec 2025
- $159.26M+9.3% YoY
- LTMMar 2026
- $154.66M-2.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 159.26M USD
- Year-over-year change
- +9.3%
- 4-year CAGR
- +52.2%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 159.26M | +9.3% |
| FY2024 | 2024-12-31 | 145.73M | +110.8% |
| FY2023 | 2023-12-31 | 69.14M | +58.5% |
| FY2022 | 2022-12-31 | 43.63M | +47.1% |
| FY2021 | 2021-12-31 | 29.67M | — |
Selling, General & Admin vs competitors
How GERN compares with its peers on the latest reported figures
- GERN's LTM Mar 2026 selling, general & admin of $154.66M is the 2nd highest of the 8 companies compared; the peer median is $16.29M.
- Its year-over-year change of -2.5% is the 5th highest of 7, against a peer median of +7.0%.
- Selling, general & admin amounts to 78.9% of revenue for GERN, versus a peer median of 24.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.4B | +8.2% | +11.2% | 24.0% | |
| LTM Mar 2026 | $154.66M | -2.5% | +54.0% | 78.9% | |
| LTM Mar 2026 | $118.84M | +5.8% | +1.0% | 39.6% | |
| LTM Mar 2026 | $22.18M | -32.4% | -9.0% | — | |
| LTM Sep 2026 | $16.29M | +45.3% | -0.9% | — | |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | $14.73M | +63.7% | -8.2% | — |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | $10.49M | — | — | — |
| LTM Jun 2026 | $7.41M | -56.6% | +8.2% | 21.1% | |
| Peer median (excluding GERN) | $16.29M | +7.0% | +0.1% | 24.0% | |
Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.39M | 596K | 237K | 76.99M | 183.88M |
| Cost of Revenue | 0 | 0 | 0 | 1.26M | 4.75M |
| Gross Profit | 1.39M | 596K | 237K | 75.74M | 179.14M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 98.4% | 97.4% |
| Research & Development | 85.73M | 95.52M | 125.05M | 103.74M | 73.72M |
| Selling, General & Admin | 29.67M | 43.63M | 69.14M | 145.73M | 159.26M |
| Operating Expenses | 115.39M | 139.15M | 194.18M | 249.47M | 232.97M |
| Depreciation & Amortization | 783K | 868K | 1.03M | 1.22M | 1.2M |
| EBITDA | (111.59M) | (134.15M) | (174.78M) | (154.85M) | (51.92M) |
| EBITDA Margin | -8010.7% | -22508.6% | -73747.7% | -201.1% | -28.2% |
| Operating Income | (114M) | (138.55M) | (193.94M) | (173.73M) | (53.84M) |
| Operating Margin | -8183.7% | -23246.6% | -81832.9% | -225.6% | -29.3% |
| Interest Income | 527K | 2.53M | 18.15M | 19.61M | 18.12M |
| Interest Expense | 3.74M | 6.88M | 8.31M | 18.5M | 32.66M |
| Other Income / Expenses | (2.11M) | (3.35M) | 9.82M | (840K) | (31.95M) |
| Income Before Tax | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Pre-Tax Margin | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (116.11M) | (141.9M) | (184.13M) | (174.57M) | (85.78M) |
| Net Margin | -8335.4% | -23808.9% | -77690.7% | -226.7% | -46.7% |
| EPS (Basic) | (0.37) | (0.37) | (0.32) | (0.27) | (0.13) |
| EPS (Diluted) | (0.37) | (0.37) | (0.32) | (0.27) | (0.13) |
| Weighted Avg Shares | 327.63M | 380.78M | 570.65M | 646.03M | 666.66M |
| Weighted Avg Shares (Diluted) | 327.63M | 380.78M | 570.65M | 646.03M | 666.66M |
Geron Corporation
NASDAQ:GERN
Intrinsic Alpha fair value
Locked
Current Price
$0.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.